The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Lindy has always said that citrullination occurs on many different proteins and within each protein specific epitopes.
Modi-1 comprises just three citrullinated peptides, two derived from vimentin and one from α-enolase.
From memory, Lindy's team initially identified of the order of 30 different citrullinated epitopes that could be targeted. At the time 8 had been tested and all 8 showed a promising response.
I think the point that Lindy is making is that Modi1 could possibly just be scratching the surface of what could be eventually achieved by targeting citrullination.
So, I think miavoce is correct in stating
"Universal could equally well mean that it can be applied to all / multiple cancers as citrullination is a common feature across them."
Ee
Possibly but they also used that term for SCIB1 which of course is a melanoma only vaccine and nothing to do with citrullination so I still think Chelsea's off the shelf as opposed to personalised is the intended meaning. Quite right too to highlight the advantage of Scancell's vaccines over those generating so much interest and excitment from BioNTech/Moderna .
The “Universal cancer vaccine” comment refers to a process (citrullination) which is common across a number of tumour types. Hence if you target the process, you can address different types of cancer and target T-cells at them.
The distinction between personalised vaccines and “ready made” alternatives is, IMO, somewhat different. But, either way, the vaccine has potentially got a broad range of applications.
Chelsea, I agree - am pretty it's universal as distinct from personalised cancer vaccines.
It could also mean that all stressed cancer cells go through citrullination and can therefore be targeted. The trick being that you have to create an environment where that stress occurs.
That is not an easy task but with enough research into the mechanisms plus the added aggression of the immune system created by Checkpoint Inhibitors, would it not be possible in all cases ??
Topped up again at 9.5p the spread is up to 5.37%.
Most probably another AIM loser rampped on this site , a site which it is very difficult to find owner off.
Universal could equally well mean that it can be applied to all / multiple cancers as citrullination is a common feature across them.
I would assume universal, is just a substitute for off the shelf.
Just looking at the link to Lindy’s talk at the Immuno-Oncology Summit, Lindy makes reference to a "universal cancer vaccine". Maybe I am mistaken but I have not heard her refer to a "universal cancer vaccine" previously :-
https://www.immuno-oncologyeurope.com/cancer-vaccines#RobertMeehan
"SCIB1 a DC targeting DNA vaccine gives at impressive 85% response rate in combination with ipilimumab and nivolumab in advanced melanoma. Citrullination occurs in stressed tumor cells and makes an excellent target for a universal cancer vaccine. Modi-1 targeting citrullination is currently in phase II clinical trial."
My guess is that they will be getting close to the 30 results that was talked about at the AGM.
The comment was that's what big pharma needed.
Interesting times might not be far away
Results as a mono therapy will show about a 60% rate similar to Scib1 as a mono. It is Sclp belief that in combination with the CPI rates will again be similar to the SCIB1 combo.
Up at the 85 to 90%
Re:Modi-1…careful choice of wording ..old data good progress not exited. Looks below expectation.
Cheer up Rob . . .
C11 - I agree. An address to an audience is far better than a Poster although some Attendees will no doubt pick out a particular Poster from the program, visit and ask questions.
Yes hard on the heels of AACR last week. Good !
Like many Investors I have for a long time a great Interest In Sclp but l don't have the funds to buy a major share In the Co. IMO.
The market as you put it appears to have little interest in anything !!!!
Morning
The title of the presentation is intriguing
"Clinical Update on the DC Targeting Melanoma Vaccine, SCIB1 and The Modi-1 Vaccine Targeting Citrullination"
“DC Targeting Melanoma Vaccine”
Dendritic cells (DCs) are a heterogeneous group of antigen-presenting innate immune cells that regulate adaptive immunity, including against cancer. Therefore, understanding the precise activities of DCs in tumours and patients with cancer is important.
This is an excellent article in nature 24th of Feb
Dendritic cells as orchestrators of anticancer immunity and immunotherapy
https://www.nature.com/articles/s41571-024-00859-1
Key points
* Combining DC-based anticancer treatments with other (immuno)therapies has shown promise in preclinical studies; however, patient selection, treatment sequencing and immunomonitoring require optimization in clinical studies to identify the most synergistic combinations.
* The development of improved DC-based anticancer treatments, including agents targeting DCs in vivo and natural DC-based vaccines produced ex vivo, has the potential to improve patient outcomes and such treatments are generally safe.
Better to be presenting / speaking to an audience who have chosen to be in the room for that topic, than smiling at folks wandering post your poster, looking for refreshments. Big difference imo. It’s a talk, 30mins allocated for it and another big chance to impress / raise the Company profile. Don’t care what the market thinks of the RNS today!
My point is I just wondered if the comment deliberately vague i.e. the "significant interest in the clinical development of therapeutic cancer vaccines", sounds like a general comment amount the market as a whole, but could it be a subtle clue for something more specific to Scancell's therapeutic cancer vaccines?
Just IMO interesting use of wording.
Yes, that was very positive and the best part of the RNS. Market still not interested.
Interesting last sentence?
"...Following on from AACR, there has been significant interest in the clinical development of therapeutic cancer vaccines, and I am excited to demonstrate the progress Scancell has made in this class of immunotherapies."
WTP
Good spot but no, that SH01 relates to two different tranches of shares and are in addition to the 1m exercised by Richard Goodfellow. Number of share options being exercised this time - 120k @ 8.15p and 40K @ 5.25p. Total shares in issue now stands at 928979977.
You may remember that in May 2020 the senior management team took a 25% pay cut for 3 months due to Covid. At the same time they were all granted 1m share options each with a strike price of 8.15p. So John Chiplin, Cliff Holloway, Lindy Durrant, Sally Adams, Richard Goodfellow and Keith Green all have 1m options at 8.15p - could be any one of those but the small no. of shares involved makes me think that it's more likely to be other members of staff exercising options awarded as part of the Company's share incentive scheme.
Scancell’s Web page still has errors.....LDs options @ 4.5p with the wrong expiry date. The option date was extended .
This conference is in Scancell's Q4 so just maybe we will have long awaited trial updates either before or the day after Lindy presents.
Lindy's presentation is followed by
"11:30-12:30 expo & partnering break"
in which Lindy will no doubt secure 2 massive deals 😂
Https://find-and-update.company-information.service.gov.uk/company/06564638/filing-history
@JB1 is thus the correction you were expecting?